OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) has been one of our favorite new players in the $7.1 billion prostate cancer treatment market. The company just put out a new press release summarizing data that makes a strong case in the preparation of a coming Phase II trial of ProscaVax, which is OncBioMune’s lead pipeline asset. As noted […]
EmailWire Instagram
This error message is only visible to WordPress admins
Error: No connected account.
Please go to the Instagram Feed settings page to connect an account.